Study objective-To compare responses of blood pressure to the calcium antagonist verapamil and the 13 blocker metoprolol in black compared with white diabetics with hypertension and to monitor urinary albumin excretion in relation to fall in blood pressure.
random order crossover trial with four week placebo run in period and two six week active phases separated by a two week placebo washout period.
Setting-Outpatient department of a general hospital in a multiethnic health department.
Patients-Diabetic patients with hypertension. Four dropped out before randomisation; 25 black and 14 white patients completed the trial.
Interventions-Patients given slow release verapamil 120 mg or 240 mg twice daily with placebo or metoprolol 50 mg or 100 mg twice daily with placebo. Treatment for diabetes (diet alone or with oral hypoglycaemic drugs) remained unchanged.
End point-Comparison of changes in blood pressure in the two groups taking both drugs.
Measurements and main results-Metoprolol had little effect on blood pressure in black patients (mean fail 4-0 mm Hg systolic (95% confidence interval -2 5 to 10*4 mm Hg), 4-3 mm Hg diastolic (-0-8 to 9 .5)) but more effect in white patients (mean falls
Introduction
Black people of West Indian descent in Britain are generally thought to have more problems with hypertension than white people and to be less easy to treat because they may not take their tablets and hence have more complications. Evidence for this view is poor. Contrary to experience in the United States recent studies in Britain found no difference in average blood pressure between black and white subjects but found a higher body mass index in black women. I2 The rate of coronary heart disease in black people has been about half that in white people, a deficit not made up by the increased rate of strokes in black people occurring at an older age. 34 Causes other than coronary heart disease are thus more important in black people.
Standardised mortality ratios for hypertension and particularly for diabetes are high in people of West Indian or African birth.3 The two conditions (diabetes being almost exclusively non-insulin dependent) commonly occur together in middle and old age.5 '7 Effective treatment of hypertension is vital.8'0 The choice of treatment, however, is awkward: although diuretics are reported to be more effective than 13 blockers in black Americans, possibly because black people tend to have low renin hypertension, they cause hyperglycaemia." 12 Angiotensin converting enzyme inhibitors have the same limitations,'3 though calcium antagonists may be more effective in patients with low renin hypertension. 14 The lack of effect of 13 blockers is sometimes blamed on poor compliance with treatment by black patients. To test this in a clinical trial and to compare results with those obtained with a calcium antagonist we mounted a randomised double blind controlled trial of a calcium antagonist (verapamil) and a 13 blocker (metoprolol) in black compared with white diabetics. We also examined whether controlling high blood pressure altered or reduced urinary albumin excretion even within its normal range.
Methods
Patients aged up to 70 were invited to join the trial if their blood pressure was high (> 160 nun Hg systolic or >95 mm Hg diastolic) on two occasions on routine screening in the diabetic clinics at Central Middlesex and Willesden Hospitals or if they were known to have hypertension and were not taking more than two treatments. All the patients had non-insulin dependent diabetes and were treated with either diet alone or diet and oral hypoglycaemic drugs. They had normal renal function (plasma creatinine concentration < 130 [tmol/l), and their urine yielded negative results on dip stick testing for albumin. The black patients were all of West Indian and hence African descent and had been born in the West Indies; we specifically excluded West Indian people of east Indian origin and black Africans. The white patients were all Europeans.
We used a double blind randomised crossover technique, with patients taking placebo for four weeks before randomisation; patients who were already taking a treatment for hypertension stopped it and were given placebo. The patients then took one of the two active drugs with a placebo matched to the other for six weeks, and, after a two week washout period when they took both placebos, they took the other active drug and placebo for a further six weeks. They were reviewed every fortnight for four visits to check for a rise in blood pressure >200 mm Hg systolic or >110 mm Hg diastolic, or both, which was a criterion for withdrawal, or 
Results
Recruitment was stopped after 27 black and 16 white patients had entered the run in placebo period. Two black and two white patients withdrew before randomisation (one owing to impaired renal function). The remaining 25 black and 14 white patients completed the trial.
The characteristics of the patients, including known duration of diabetes, were comparable, though the black patients were slightly younger, had a lower body mass index, and contained a larger proportion of women (Table I ). The number taking oral hypoglycaemic drugs was similar in both groups; the average dose was 850 mg metformin alone twice daily, 7-5-10 0 mg glibenclamide alone daily, or 850 mg metformin plus 7 5 mg glibenclamide daily. Complications of diabetes were mild (table I); no patient had autonomic neuropathy, and one white and one black patient had had laser treatment for proliferative retinopathy.
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systolic; df=24; p>04); in the white patients systolic (with a wide confidence interval) and diastolic pressures fell when they were taking metoprolol (mean=12-0 mm Hg; t=3 75 diastolic and 2-18 systolic; df= 13; p=0-002 and 0-048 respectively). The overall fall in blood pressure was greater with verapamil than metoprolol and was greater in white than black patients (table II) . Individual values confirmed these mean results, with only five of the black patients showing falls in blood pressure >8 mm Hg while taking metoprolol (fig 1) ; only two of the white patients had falls <8 mm Hg. In the 14 white patients blood pressure fell with both drugs; there was a consistent dose response which was greater than that in the black patients, whose blood pressures had fallen at two weeks but no further by. six weeks (fig 2) . These differences remained significant when age and differences in baseline blood pressure were taken into account by analysis of covariance.
Though blood pressure did not fall in the black patients when they took metoprolol, heart rates fell significantly and only slightly less than in white patients (table II) . No overall change was seen when patients took verapamil. Changes in heart rate and in blood pressure were not correlated, either in those black patients in whom there was at least some fall in pressure or in the white patients, or in the groups combined.
METABOLIC RESULTS
Glycaemic, lipid, and C peptide profiles-Analysis of variance showed that mean haemoglobin AI concentrations were unaltered during each treatment phase in black and white patients (baseline values 11 1% and 9-2% respectively); similarly fasting blood glucose concentrations were unchanged, though values were higher throughout in the black than the white patients (overall mean (SD) 9-5 (14) v 7-7 (1-3) mmol/l, respectively; p<001). The serum total cholesterol concentrations were also unchanged during each treatment period but were significantly lower in the black than white patients (overall mean 5*96 (1-4) v 6-36 (I-1) mmol/l; F1,218=8-2; p<001), yet the concentration of high density lipoprotein cholesterol was considerably higher in the black than white patients (1-57 (039) Plasma renin activity-The geometric mean plasma renin activity was low in both groups and was significantly lower in the black than white patients initially (0-42 v 0 55 nmol/l/h) and after verapamil treatment (p<0001) (fig 3) . In both groups, though to a lesser extent in black patients and despite the lack of a fall in blood pressure, the activity was further suppressed by metoprolol. There was no significant relation between change in blood pressure and baseline renin activity or change in renin activity.
Urine albumin, creatinine, and electrolyte concentrations-Urinary albumin excretion, measured in timed overnight samples on six occasions over 18 weeks, was within the normal range (<30 mg/l) in both the white and black patients except in one black woman with microalbuminuria (in whom it varied from 66 to 149 mg/l). Using the ratio of urinary albumin to creatinine excretions to correct for volume produced similar means shown by bold line differences in age). Urinary electrolyte concentrations did not differ between the groups or through the trial. The mean change in the urinary albumin:creatinine ratio between the start and end of either treatment was a decrease of 20-3% (from 0-78 to 0-64) for 60 paired values (95% confidence interval 23% to -89%). Thus the treatment had no significant effect on urinary albumin:creatinine ratio (or urinary albumin). Baseline urinary albumin excretion was, however, related to initial systolic blood pressure in the group as a whole, both supine (r=0-28; n=39; p<002) and standing (r=0 35; p<001), owing to a stronger relation in the black patients (supine r=0-36; standing r=0 55).
Discussion
This study confirms the limited effect of a 13 blocker in black patients: the mean blood pressure did not fall when the patients took metoprolol, though there was a limited response in individual patients. The effect of verapamil in reducing blood pressure was more uniform among the black patients, averaging 9/8 mm Hg, but was more pronounced in the white patients (19/11 mm Hg) . Despite some differences in baseline factors between the black and white patients the analysis of variance substantiated the difference in drug response between black and white people. A crossover trial, particularly with a placebo run in period and a double dummy technique, is one method of dealing with the fall in blood pressure that occurs with repeated measurements.
To our knowledge there are no previously published trials on blood pressure specifically comparing black with white patients in Britain, where 13 blockers remain common as monotherapy. About half of the black patients with hypertension referred to our clinic from general practice and taking monotherapy are taking (3 blockers, though the limitations of these drugs in black patients have been described in double blind trials. One trial, of atenolol, was carried out in South Africa,'5 where social conditions are poor and black people are of different genetic origin to those whom we studied. In the United States the Veterans Administration trial of parallel design compared propranolol and hydrochlorothiazide and found similar results. ' 12 A study from Jamaica showed that black patients required higher doses of atenolol and responded better to chlorthalidone (a thiazide). 16 The difference in response between black and white patients is abolished when black patients take a thiazide with the 13 blocker. This has been shown in black patients of different origins in the United States,'7 the Caribbean, '8 and Kenya (N Poulter, personal communication).
A clear dissociation was seen in our study between the response of the heart rate to the 13 blocker and the lack of fall in blood pressure in the black patients. Their mean fall in heart rate was about 14 beats/ minute, which was much the same as that in the white patients (17 beats/minute); no overall change occurred when either group took verapamil. This indicated compliance with the treatment among both groups of patients and tablet counts showed that over 92% of tablets had been taken at every visit.
The poor response of blood pressure to 13 blockers in black patients has been related to low plasma renin activity.'2 1 ' In our patients renin activity was already low, and this may be a feature of diabetics with hypertension in any ethnic group.8 Renin activity was slightly suppressed in the black patients while they received the 13 blocker (fig 3) but did not help to predict individual response to treatment. In the white patients and in the groups combined there was no relation between initial renin activity and change in blood pressure, contrary to previous reports. '4
The mechanism of suppression of renin in black populations, which is present in early childhood, is unknown.20 Estimates of urinary sodium excretion do not support excess salt intake as a cause of the lower renin activity in black people, whether as children or adults.2' 22 No difference in sodium excretion between or within groups was found on the six occasions that it was measured here.
The No effect on urinary albumin excretion was seen, but this study was too small to detect an overall effect or a difference between drugs. Possibly, afferent renal arteriolar blood pressure is the main determinant of filtration pressure and hence urinary albumin excretion, which may also be modified by the effects of drugs on the efferent renal arteriole. If so, 13 blockers with no effect on renal blood flow (such as metoprolol) would alter urinary albumin concentration less than other drugs (such as angiotensin converting enzyme inhibitors and calcium antagonists). A beneficial effect of captopril on protein loss in overt diabetic nephropathy has been reported in two studies.2930 In a third study the fall in glomerular filtration over two years was slowed down, though the relation to change in blood pressure was not examined.3' In our study the 95% confidence interval for the change in the ratio of urinary albumin to creatinine excretion between the start and end of treatment was large. At least twice the number of patients would be required to test the hypothesis that reducing the blood pressure of hypertensive diabetics decreases albumin excretion even within its normal range.
The baseline urinary albumin excretion was positively correlated with initial systolic blood pressure. This relation was independent of age, body mass, and haemoglobin AI concentration. We recently reported similar findings: in non-diabetics the ratio of urinary albumin to creatinine excretion in a spot sample of urine collected during the day was related to systolic blood pressure in a random sample of non-diabetics with normal renal function32 and in a random sample from a diabetic population. 33 Thus, epidemiologically and possibly clinically, urine albumin excretion may reflect the blood pressure.
In conclusion, it seems that even with drugs such as calcium antagonists, to which black patients do BMJ VOLUME 297 respond, the degree of response of blood pressure is less for a given dose in black than white patients. There are no ideal antihypertensive drugs for black patients, and these data suggest that poor compliance does not account for the failure to control blood pressure. 
